Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Melinda K. Lacy"'
Publikováno v:
Open Forum Infectious Diseases
Background Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive organisms, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. New onset or worsening renal impairment was obs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914aa95ab4182c418e0c23a4ba1ae3c3
http://europepmc.org/articles/PMC6255214
http://europepmc.org/articles/PMC6255214
Autor:
Claire Sherman, Melinda K. Lacy, Steven L. Barriere, Jamie P. Dwyer, Kieren A. Marr, Thomas C. Hardin, Lee E. Morrow, Jon Bruss, Boris Nogid
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ab6de46d5b997803fd2e83b93aec9e8
https://doi.org/10.1093/ofid/ofw172.963
https://doi.org/10.1093/ofid/ofw172.963
Autor:
G. Ralph Corey, Andrew F. Shorr, Melinda K. Lacy, Thomas C. Hardin, David R. Luke, Steven L. Barriere, Whedy Wang, Boris Nogid, Martin E. Stryjewski
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 61
BACKGROUND When hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positive and gram-negative pathogens or both (mixed infections), the adequacy of gram-negative coverage (GNC) can confound the assessment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb34aa023829dbc0015b72b55f47a283
https://pubmed.ncbi.nlm.nih.gov/26316562
https://pubmed.ncbi.nlm.nih.gov/26316562
Publikováno v:
Hospital Pharmacy. 39:542-553
Antibiograms are an important resource for health care providers. All clinicians involved in antibiotic selection and monitoring should become familiar with the NCCLS M39-A document “Analysis and Presentation of Cumulative Antimicrobial Susceptibil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce162f2e0c298ebfa9310aa786421ab5
https://doi.org/10.1177/001857870403900608
https://doi.org/10.1177/001857870403900608
Publikováno v:
Open Forum Infectious Diseases
Background Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). Bone and joint infections represent a comple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc7c56c700687ac3a0409f7ac6ce6943
http://europepmc.org/articles/PMC5632217
http://europepmc.org/articles/PMC5632217
Autor:
David P. Nicolau, JoCarol McNabb, Melinda K. Lacy, Richard Quintiliani, Charles H. Nightingale
Publikováno v:
International Journal of Antimicrobial Agents. 17:497-504
A prospective, randomized pilot study was undertaken to compare the efficacy of continuous versus intermittent ceftazidime in ICU patients with nosocomial pneumonia. Ceftazidime was administered either as a 3 g/day continuous infusion (CI) or an inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9a8982cc949e5ad7c3fcad0a2cdb7c
https://doi.org/10.1016/s0924-8579(01)00329-6
https://doi.org/10.1016/s0924-8579(01)00329-6
Publikováno v:
American Journal of Health-System Pharmacy. 58:379-388
The activity, pharmacokinetics, pharmacodynamics, efficacy, safety, drug interactions, and dosage and administration of moxifloxacin are reviewed. Moxifloxacin is an oral 8-methoxyquinolone antimicrobial approved in December 1999 for use in the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::239d41123e825aeb16dd9cda594bce97
https://doi.org/10.1093/ajhp/58.5.379
https://doi.org/10.1093/ajhp/58.5.379
Autor:
Elaine M. Bailey, David S. Burgess, Melinda K. Lacy, Michael A. Pfaller, George G. Zhanel, Michael E. Klepser, Erika J. Ernst, Peggy L. Carver, David P. Nicolau, Renee-Claude Mercier, Russell E. Lewis, C. Rosemarie Petzold
Publikováno v:
Journal of Infectious Disease Pharmacotherapy. 5:29-41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c6907b8ee2ae4b0852d9020ce42cd6
https://doi.org/10.1300/j100v05n02_04
https://doi.org/10.1300/j100v05n02_04
Autor:
David P. Nicolau, Charles H. Nightingale, JoCarol McNabb, Marc Rousseau, Jack W. Ross, Melinda K. Lacy
Publikováno v:
Infectious Diseases in Clinical Practice. 9:27-32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5fe19463d09145eaec8ca597d0058c9
https://doi.org/10.1097/00019048-200009010-00008
https://doi.org/10.1097/00019048-200009010-00008
Publikováno v:
Clinical Pharmacokinetics. 36:353-373
Metronidazole, the prototype nitroimidazole antimicrobial, was originally introduced to treat Trichomonas vaginalis, but is now used for the treatment of anaerobic and protozoal infections. The nitroimidazoles are bactericidal through toxic metabolit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d12a1acee2ff8ea125c9513f10a71b7
https://doi.org/10.2165/00003088-199936050-00004
https://doi.org/10.2165/00003088-199936050-00004